Multifunctional Triblock Nanocarrier (PAMAM-PEG-PLL) for the Efficient Intracellular siRNA Delivery and Gene Silencing by Patil, Mahesh L. et al.
PATIL ET AL. VOL. 5 ’ NO. 3 ’ 1877–1887 ’ 2011 1877
www.acsnano.org
February 15, 2011
C2011 American Chemical Society
Multifunctional Triblock Nanocarrier
(PAMAM-PEG-PLL) for the Eﬃcient
Intracellular siRNA Delivery and Gene
Silencing
Mahesh L. Patil, Min Zhang, and Tamara Minko*
Department of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, New Jersey 08854, United States
D
esign and creation of novel nano-
meter-size carriers for the safe deliv-
ery of small interfering RNA (siRNA)
towardtheirpotentialapplicationsincancer
therapy is one of the challenging and ra-
pidly growing areas of research. RNA inter-
ference (RNAi) is a conservative biological
responsetosiRNAthatregulatestheexpres-
sion of protein coding genes.
1-5 However,
the broad therapeutic applications of siRNA
arelimitedbymajordeliveryproblems.
6The
eﬃcient invivo geneknock downrequires a
delivery system that would overcome the
followinglimitations:(1)lowcellularuptake,
(2) poor endosomal escape, (3) substantial
liver and renal clearance, (4) facile enzy-
matic degradation in the blood and extra-
cellular environment, and (5) ineﬃcient
gene silencing.
Recentinvestigationsintheareaofnano-
materials for RNA delivery, including the
works in our laboratory, provided solutions
to some of the major siRNA delivery pro-
blems.
7-16 However, the developed deliv-
eryapproaches addressonlyselectedsiRNA
deliveryproblems lackingoptimal balanced
delivery system that includes a solution for
all the major aforementioned challenges.
Forexample,abiodegradablepolymerpoly-L-
lysine (PLL) is being used for gene delivery,
and its polyplexes are taken up into cells
eﬃciently. However, transfection eﬃcien-
cies of PLL-siRNA complexes remain sev-
eral orders of magnitude lower when
compared that of other transfection agents.
Onepotentialreasonforineﬃcienttransfec-
tionhasbeenidentiﬁedasthelackofamino
groups with a pKa ∼5-7 for so-called “pro-
ton sponge eﬀect” that oﬀers endosomoly-
sis and subsequent release of siRNA. The
desired transfection eﬀect was achieved by
structuralmodiﬁcationofPLLusingatargeting
ligand or endosomolytic agents such as
chloroquine or fusogenic peptides.
17,18 A
signiﬁcant improvement in transfection ef-
ﬁciency was observed when histidine or
imidazole moieties were attached to the
PLL.
19,20
Another major challenge in the safe de-
livery of siRNA is its facile enzymatic degra-
dation in cytoplasm due to the presence of
nucleases that dramatically reduce siRNA
half-life. Previously, we have reported that
internally quaternized and cancer-targeted
polyamidoamine(PAMAM)dendrimerspro-
vide for the eﬃcient cellular uptake and
excellent gene silencing.
14 It was shown that
surface modiﬁcation and internal quaterni-
zationofdendrimersreducedtheircytotoxi-
city and substantially improved the cellular
uptake,whiletargetingofthedendrimersto
cancer cells initiated receptor-mediated en-
docytosis and led to the eﬃcient gene
knock down. We have also demonstrated
the importance of free tertiary amine groups
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ABSTRACT A novel triblock poly(amido amine)-poly(ethylene glycol)-poly-L-lysine (PAMAM-
PEG-PLL)nanocarrierwasdesigned,synthesized,andevaluatedforthedeliveryofsiRNA.Thedesign
of the nanocarrier is unique and provides a solution to most of the common problems associated
withthedeliveryandtherapeuticapplicationsofsiRNA.Everycomponentinthetriblocknanocarrier
plays a signiﬁcant role and performs multiple functions: (1) tertiary amine groups in the PAMAM
dendrimer work as a proton sponge and play a vital role in the endosomal escape and cytoplasmic
deliveryofsiRNA;(2)PEG,alinkerconnectingPLLandPAMAMdendrimersrendersnucleasestability
andprotectssiRNAinhumanplasma;(3)PLLprovidesprimaryaminestoformpolyplexeswithsiRNA
through electrostatic interaction and also acts as penetration enhancer; and (4) conjugation to PEG
and PAMAM reduced toxicity of PLL and the entire triblock nanocarrier PAMAM-PEG-PLL. The data
obtained show that the polyplexes resulted from the conjugation of siRNA, and the proposed
nanocarrierswereeﬀectivelytakenupbycancercellsandinducedtheknockdownofthetargetBCL2
gene.Inaddition,triblocknanocarrier/siRNApolyplexesshowedexcellentstabilityinhumanplasma.
KEYWORDS: siRNA delivery . PAMAM dendrimer . BCL2 silencing . siRNA stability
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in dendrimers for endosomal escape. The present
study explores a diﬀerent approach and is aimed at
the design, synthesis, and evaluation of a triblock
delivery system that provides solutions for major pro-
blems in siRNA delivery, such as poor cellular uptake,
low endosomal escape, and facile enzymatic degrada-
tion. A novel triblock nanocarrier, PAMAM-PEG-PLL,
has been designed to combine individual features of
PAMAM dendrimer, polyethylene glycol (PEG), and
poly-L-lysine. PAMAM dendrimer provides tertiary
amines for endosomal escape; PEG covers up siRNA,
protecting it from enzymatic degradation, while PLL
oﬀers cationic amine groups for electrostatic interac-
tion with negatively charged siRNA.
RESULTS AND DISCUSSION
Delivery of siRNA into the cytoplasm of cancerous
cells where it triggers sequence-speciﬁc mRNA degra-
dationhasrecentlyemergedasapowerfultoolingene
therapy. The major obstacles in safe transportation of
siRNA have been extensively investigated, and con-
densation to nanoparticles has now been recognized
as the most eﬃcient method for facile transport of
siRNA. Therefore, designing a nanocarrier that enables
eﬀective and safe transfer of siRNA into mammalian
cells is a task of great interest. We are actively involved
in the design, synthesis, and evaluation of various
multifunctionalnanoparticlesassiRNAdeliverycarriers
that include liposomes, surface-modiﬁed dendrimers,
mesoporous silica nanoparticles, and surface-engi-
neered superparamagnetic iron oxide (SPIO) nanopar-
ticles, etc.
7,11,13,14,16,21-25 In general, combining
multiple functions in a single delivery system is a
diﬃcult task and requires laborious synthetic eﬀorts.
In continuation with our previous studies on develop-
ing multifunctional nanomedicines, herein we de-
scribe the design, synthesis, and evaluation of a
synthetically simple yet novel triblock multifunctional
nanocarrier, PAMAM-PEG-PLL, that eﬀectively com-
bines three functionalities which are otherwise inef-
fective when tested individually. The triblock nano-
narrier PAMAM-PEG-PLL serves three distinct func-
tions: (1) PLL provides cationic primary amine groups
for electrostatic interaction with negatively charged
siRNA; (2) PAMAM dendrimer oﬀers necessary tertiary
amine groups for proton sponge eﬀect; while (3) PEG
confers nuclease stability in blood serum.
A three-step synthetic route was used for the pre-
paration of PAMAM-PEG-PLL nanocarrier (Scheme 1).
In the ﬁrst step, PAMAM dendrimer was partially
acetylated to aﬀord PAMAM-[(NHAc)58(NH2)6] dendri-
mer. The second step involved synthesis of PAMAM-
PEG-COOHbyreactingoneoftheacidgroupsofR,ω-bis-
(2-carboxyethyl)polyethylene glycol (Mw = ∼3000) with
one of the primary amines of the PAMAM-[(NHAc)58-
(NH2)6]dendrimer.Onecouldexpectthatthelengthof
the PEG block would have great inﬂuence on the ﬁnal
triblock-siRNA complex as a shorter length might not
be enough to protect siRNA from the enzymatic de-
gradation. However, the exact length of PEG required
to achieve eﬃcient siRNA protection is unknown.
Instead of using a single long PEG chain length, we a
used medium size chain (Mw = 3000), while the ratio of
triblock nanocarrier/siRNA was taken as 3 (N/P = 3).
Thus, a single siRNA is surrounded by three PEG blocks
and expected to give eﬀective protection. Previously,
wetestedthecellularpenetrationofPEGwithdiﬀerent
molecular weight (up to Mw = 20000 Da) and found
that PEG with Mw around 3000 Da penetrates cells
faster when compared with higher Mw polymers.
26 On
thebasisoftheseconsiderations,weselectedPEGwith
Mw = 3000 Da for these studies. During the third step,
the terminal free acid group of PAMAM-PEG-COOH
was reacted with PLL using EDC as a coupling reagent.
One can assume that the synthetic procedure used
could not be selective and the design led to some
cross-linking reactions. However, we are certain that
our synthetic scheme can be selective because it is a
sequential procedure and the following reasons con-
tribute to the selective formation of PAMAM-PEG and
not a PAMAM-PEG-PAMAM cross-linking polymer: (1)
PAMAM-NHAc has only 5-6 free amines to react with
thePEG-dicarboxylicacid;(2)thefreeaminegroupson
thedendrimerarecrowdedwithNHAcsubstituentand
not easily available for cross-linking; (3) dilution of
reaction also plays an important role in reducing the
cross-linking reaction; (4) this reaction greatly diﬀers
fromtheusualsmallmoleculeswhereselectivitywould
be an issue; (5) in the present studies, more harsh
conditions,prolongedreactiontime,andmoreequiva-
lents of coupling reagents would be required to force
the cross-linking PAMAM-PEG-PAMAM reaction; (6) we
followed the usual technique of ﬁltering the reaction
mixture after coupling reaction to remove any insolu-
ble material; however, in this reaction, negligible
amount of insoluble material was formed; (7) even if
the cross-linking product is formed, it was in trace
amounts and removed completely during ﬁltration.
The coupling reaction of PAMAM-PEG with PLL can
be selective to form the desired PAMAM-PEG-PLL as
PLL has several amine groups available to react in
comparison with 5-6 amine groups of the PAMAM
dendrimer. The
1H NMR was very useful and informa-
tive in determining the content of the nanocarrier. The
areaunderthepeakwouldgreatly vary(almostdouble
or half) if the number of units (PAMAM, PEG, and PLL)
changes in the ﬁnal nanocarrier. Each block has a large
number of protons and cannot be ignored.
Theoretically, there might be a possibility that some
moleculesofsiRNAcouldformcomplexesdirectlywith
the PAMAM dendrimer, not with positively charged
PLL. The PAMAM dendrimer used in the present study
was surface-modiﬁed and lacks free primary amine
groups required to form a complex with siRNA. As
1H
A
R
T
I
C
L
EPATIL ET AL. VOL. 5 ’ NO. 3 ’ 1877–1887 ’ 2011 1879
www.acsnano.org
NMR studies show, very few (∼5-6) free amines are
availableonthePAMAMdendrimer.Suchanamountis
notenoughtoformcomplexeswithsiRNAthatpossess
about 42 negatively charged phosphate groups. Our
previous studies on quaternized QPAMAM-OH den-
drimers suggested that tertiary amines in the PAMAM
dendrimer do not participate in direct complexation
with siRNA, and a stable complex is formed only after
quaternizing the internal tertiary amine groups.
14 This
supports the fact that the PAMAM dendrimer would
not form a complex with siRNA.
Weattemptedtodeterminethemolecularweightof
the nanocarrier by MALDI-TOF; however, even after
several trials, the triblock nanocarrier did not show
clear mass. The following three matrix compounds
were used to record MALDI-TOF: sinapinic acid, R-
cyano-4-hydroxycinnamic acid,and2,5-dihydroxyben-
zoic acid. More than likely, the triblock nanocarrier did
not ionize under the attempted conditions. All proton
NMR spectra were recorded in solution of studied
compounds in D2O using a 400 MHz NMR spectro-
meter.Thechemicalshift(δ)wasexpressedaspartsper
million (ppm). The data obtained conﬁrmed the struc-
tures of synthesized substances. PAMAM-NHAc
1H
NMR spectral data are shown in Figure 1a. The follow-
ing peaks were identiﬁed: δ 1.98 (s, COCH3), 2.40-2.50
Scheme 1. Synthesis of triblock PAMAM-PEG-PLL nanocarrier.
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(br m, CH2CONH), 2.62-2.73 (br m, CONHCH2CH2N),
2.82-2.92 (br m, NCH2CH2CONH), 3.26-3.37 (m,
CONHCH2 and CH2NHCOCH3). The degree of acetyla-
tion (∼90%) was conﬁrmed from the proton NMR
spectra (Figure 1a) and by calculation, the ratio be-
tweentheintegratedpeakareaofsignalappearedatδ
1.98ppm(-NHCOCH3)tothatofmethyleneprotonsof
the PAMAM dendrimer (δ 2.40-3.37). PAMAM-PEG-
COOH
1H NMR spectrum (Figure 1b) showed the
following peaks: δ 2.00 (s, COCH3), 2.40-2.50 (br m,
CH2CONH), 2.64-2.75 (br m, CONHCH2CH2N), 2.82-
2.92 (br m, NCH2CH2CONH), 3.30-3.38 (m, CONHCH2
and CH2NHCOCH3), 3.74 (s, -CH2CH2O). The spectra
showedmonoacylationofthe dendrimerwithR,ω-bis-
(2-carboxyethyl)polyethylene glycol, leaving another
-COOH group free for conjugation with poly-L-lysine
(PLL). The
1H NMR spectra for this compound con-
ﬁrmed the presence of both polyethylene glycol and
dendrimer protons. Further monofunctionalization
was determined by calculating the area under the
proton peaks arising from polyethylene glycol (Mw =
∼3000,-CH2CH2O-,∼270H) anddendrimer(-COCH3,
174 H) appeared at δ 3.74 and δ 2.00, respectively.
PAMAM-PEG-PLL
1H NMR spectral data are shown in
Figure2c.Thefollowingpeakswereidentiﬁed:δ1.30-
1.50(brm,PLL),1.60-1.90(brm,PLL),1.98(s,PAMAM),
2.40-2.50 (br m, PAMAM), 2.60-2.70 (br m, PAMAM),
2.78-2.88 (br m, PAMAM), 2.90-3.05 (br m, PLL),
3.26-3.37 (m, PAMAM), 3.70 (s, PEG), 4.25-4.35 (br m,
PLL). The spectra conﬁrmed the formation of the
PAMAM-PEG-PLL nanocarrier showing the presence
of proton peaks arising from dendrimer (PAMAM),
polyethylene glycol (PEG), and poly-L-lysine (PLL).
PEG-PLL
1H NMR spectrum (Figure 1d) showed the
following peaks: δ 1.38-1.60 (br m, -CH2-CH2-CH2-),
1.68-1.90 (br m, -CH2-CH2-CH(CO)NH- and -CH2-
CH2-CH2NH2-), 2.90-3.10 (br m, -CH2-CH2NH2-),
3.70 (s, -CH2CH2O PEG), 4.30-4.40 (br m, -CH2-CH2-
CH(CO)NH-).
1HNMRtechniquehasbeenwidelyused
and documented as one of the best methods for
Figure 1. Representative
1H NMR spectra in (a) D2O of PAMAM-NHAc; (b) PAMAM-PEG-COOH; (c) PAMAM-PEG-PLL; (d) PLL-
PEG-OMe.
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calculating the functional group content of dendri-
mers. The number of amine groups left free after
acetylation reaction can be calculated using the
1H
NMR technique.
27 Since the triblock nanocarrier is a
combination of linear as well as spherical polymer, it
will not follow the behavior of the conventional poly-
mer molecules, and therefore, the conventional mo-
lecular weight determination method based on
calibration cannot be used in such cases. More studies
and special setups are required to use the gel permea-
tion chromatography (GPC) method to determine the
molecularweight.Wefoundthat
1HNMRspectroscopy
was highly useful and provided the desired information
by comparing the area under the peak. The number of
free amines in the PAMAM-PEG-PLL nanocarrier was
calculated based on the degree of polymerization in
the poly-L-lysine polymer. There could be a very small
variation in the calculated and actual content of the
functional group in the nanocarrier; however, we
believe that it would not greatly aﬀect its function.
Gel electrophoresis studies also provided indirect evi-
dence on the accuracy of calculated content of the
functional group in triblock nanocarriers. The band for
siRNA completely disappeared when the ratio of N/P
was 1; that is, the number of cationic amines/phos-
phate of siRNA is 1/1. If the calculated amount of
cationic amines is not correct, the nanocarrier/siRNA
complex formation can be expected at a diﬀerent N/P
ratio (-NH2 of nanocarrier/phosphate of siRNA).
The measurementof viability ofcells incubated with
diﬀerentconcentrationsofPEG,PLL,PEG-PLL,PAMAM-
NHAc-PEG, and PAMAM-NHAc-PEG-PLL compounds
showed their relatively low cytotoxicity (Figure 2a).
No substantial diﬀerences were found between diﬀer-
ent nanocarriers under the concentrations of the com-
pounds lower than 4 μM. However, the concentrations
exceed 4 μM, PEG-PLL demonstrated higher cytotoxi-
city when compared with PLL alone and PAMAM-
NHAc-PEG-PLL. Therefore, the toxicity of PEG-PLL was
reduced when PEG-PLL was conjugated to the PAMAM-
NHAc dendrimer. Cytotoxicity data for the triblock
PAMAM-NHAc-PEG-PLL nanocarrier were compared
with cytotoxicity of its previously synthesized prede-
cessors (PAMAM-NH2, PAMAM-OH, and PAMAM-NHAc
dendrimers).
13 The results of such comparison showed
a comparably low cytotoxicity for triblock PAMAM-
NHAc-PEG-PLL and acetylated PAMAM-NHAc dendri-
mers. The cytotoxicity under the high concentrations
of both dendrimers was lower when compared with
quaternized the non-acetylated PAMAM-OH dendri-
mer. In contrast, nonmodiﬁed PAMAM-NH2 dendrimer
demonstrated a signiﬁcant cellular toxicity under con-
centrationshigherthan5μM.Itshouldbestressedthat
amaximumdecreaseinviabilityofcellsincubatedwith
PEG, PLL, PEG-PLL, PAMAM-NHAc-PEG-PLL, PAMAM-
OH, and PAMAM-NHAc compounds was substantially
higher than 50% under all studied concentrations.
Such low toxicity does not allow calculating the IC50
dose for these substances (half-maximal inhibitory
concentration, thedosethatkillsabout 50%ofcells).
In contrast, the IC50 dose of nonmodiﬁed PAMAM-
NH2 dendrimer was estimated to be around 6 μM
(Figure 2a).
The nanocarrier-siRNA complex formation and op-
timal N/P ratio was determined by agarose gel electro-
phoresis. The PLL, PEG-PLL, and PAMAM-PEG-PLL
nanocarriersweremixedwithsiRNAinwateratvarious
N/P charge ratios and were subjected to electrophor-
esis in agarosegel (Figure 2b). Thenumbers ofcationic
primary amine groups in PLL, PEG-PLL, and PAMAM-
PEG-PLLwerecalculatedbasedonPLLMw(∼8000)and
degree of polymerization (57). All three nanocarriers
showed the complex formation at the N/P ratio of 1 and
Figure 2. Characterization of diﬀerent nanocarriers and
their complexes with siRNA: (a) viability of human cancer
cells incubated with carriers indicated (means ( SD are
shown); (b) representative images of agarose gel electro-
phoresis of siRNA complexes with diﬀerent carriers; (c)
average hydrodynamic diameter of PAMAM-NHAc-PEG-
PLL-siRNA complexes formed at diﬀerent N/P ratio. Means
( SD are shown. *P < 0.05 when compared with N/P ratio
equal to 1.
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above as evidenced by oligonucleotide band disap-
pearance from agarose gels. The quantitative analysis
showed that ﬂuorescence of PLL-siRNA, PEG-PLL-siR-
NA,andPAMAM-PEG-PLL-siRNAprogressivelydecreased
with the increase in N/P ratio. For PLL-siRNA, the com-
plexationdecreasedﬂuorescenceto19,8,and0%with
N/Pratioequalto0.5,1.0,and1.5relativeunits,respec-
tively; for PEG-PLL-siRNA, ﬂuorescence decreased to
19, 8, and 0% with N/P ratio equal to 0.5, 1.0, and 1.5
relative units, respectively; for PAMAM-PEG-PLL-siRNA,
ﬂuorescence decreased to 45 and 0% with N/P ratio
equal to 0.5 and 1.0, respectively.
The hydrodynamic diameter of the PAMAM-PEG-
PLL-siRNA complex was determined by dynamic light
scattering at a charge ratio ranging from 1 to 3 relative
units. The PAMAM-PEG-PLL/siRNA particle size slightly
decreased by increasing the charge ratio to 3 relative
units (Figure 2c). The measurements of zeta-potential
ofdendrimer-siRNAcomplexesshowedthatthecom-
plexes were neutral. The size of the PAMAM-PEG-PLL-
siRNA complexes used in this paper varied from 120 to
180 nm depending on N/P ratio. This relatively large
size is attributed to cross-linking of nanocarrier and
siRNA. Previously, we have shown that an internally
chargeddendrimergivessmall,compact,andspherical
nanoparticles with siRNA; however, commercial PA-
MAM-NH2showednanoﬁbersduetocross-linking.
26In
the present experiments, we expect a similar trend
because PLL possesses primary amine groups.
The cellularuptake of nakedand complexated ﬂuor-
ophore-labeled siRNA (siGLO Red, red ﬂuorescence)
wasstudiedinliving(not washedandﬁxed)cellsusing
confocal microscopy. A2780 human ovarian cancer
cellswereincubatedwithfreesiRNAandPAMAM-PEG-
PLL-siRNA complex and were subjected to confocal
microscopy. Consistent with our previous ﬁndings,
13,14
nakedsiRNAdidnotpenetratethecancercells(Figure3a).
Previously, we have reported that PAMAM-NH2 and
PAMAM-OH dendrimers failed to deliver siRNA into
cells, while the acetylation of the PAMAM dendrimer
surface substantially improved internalization of PA-
MAM-siRNA complexes.
13 On the basis of this ﬁnding,
we used a PAMAM dendrimer with the acetylated
surfacefurthermodiﬁedwithPEGandPLL.Itwasfound
that siRNA complexated with a PAMAM-PEG-PLL ca-
tionic nanocarrier provided excellent cellular uptake
(Figure 3b). Moreover, optical section z-series of a single
living cell showed the homogeneous and uniform
distribution of siRNA-dendrimer complex in diﬀerent
cellular layers from the top of the cell to the bottom
(Figure3c).Wewouldliketostressagainthatallexperi-
ments were performed on living cells without staining,
ﬁxation, and washing out the media with ﬂuorescently
labeled siRNA-dendrimer complexes. Because of this,
one can see red ﬂuorescence inside both the cells and
media. In contrast, naked siRNA could be seen just in
the media but not in the cell (Figure 3a).
The stability of siRNA in the blood serum was deter-
minedbyincubating siRNAeithernakedorcomplexed
with PAMAM-PEG-PLL nanocarrier in the human blood
serum (Figure 4). As expected, naked siRNA started to
degrade after 1 h of incubation and completely de-
graded within 12 h. In contrast, complexation of siRNA
to PAMAM-PEG-PLL nanocarrier protected siRNA from
the nuclease degradation; even 48 h after the incuba-
tion of complexated siRNA with human blood serum,
siRNA remained nondegraded. Therefore, the pro-
posed complexation of siRNA with PAMAM-PEG-PLL
prevents the degradation of siRNA in the plasma.
The gene knock down eﬃciency of siRNA delivered
by poly-L-lysine (PLL), PEG-PLL, PAMAM, PAMAM-PEG,
and PAMAM-PEG-PLL nanocarriers with appropriate
controls (fresh media, naked speciﬁc siRNA, naked
nonspeciﬁc siRNA with scrambled sequence, and non-
speciﬁcsiRNAdeliveredbyPAMAM-PEG-PLLnanocarrier)
was investigated using quantitative RT-PCR. We se-
lected the BCL2 protein responsible for cellular anti-
apoptotic defense as a target for siRNA. The results of
these experiments are shown in Figure 5. It was found
Figure 3. Cellular uptake and localization of naked siRNA
and PAMAM-PEG-PLL-siRNA complexes. Representative
confocal microscopy images of cancer cells incubated with
ﬂuorophorelabeledsiRNA(siGLORed,redﬂuorescence):(a)
naked siRNA; (b) PAMAM-PEG-PLL-siRNA; (c) optical section
z-series of cells incubated with PAMAM-PEG-PLL-siRNA.
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thatsiRNAdeliveredbyPAMAM,PAMAM-PEG,PLL,and
PEG-PLL nanocarriers lowered the expression of the
targeted gene approximately up to 70-50% from its
control value (Figure 5, bars 2 and 3, P < 0.05). In
contrast, delivery of siRNA by a PAMAM-PEG-PLL tri-
blocknanocarrierledtoasigniﬁcantsuppressionofthe
expression of the targeted BCL2 gene down to 20%
from the control value (P < 0.05). The decrease in gene
expression after incubation with PAMAM-PEG-PLL-siR-
NA was statistically signiﬁcant (P < 0.05) when com-
pared with either PLL-siRNA or PEG-PLL-siRNA
complexes. It should be stressed that naked BCL2-
speciﬁc siRNA, naked nonspeciﬁc siRNA, and nonspe-
ciﬁc BCL2 siRNA conjugated with PAMAM-PEG-PLL did
not inﬂuence the expression of BCL2 mRNA.
Studies on PLL as a cationic nanocarrier for gene
transfection eﬃciency revealed that PLL alone pro-
vides relatively low gene knock down, which is attrib-
uted to the lack of tertiary amine groups for the so-
called proton sponge eﬀect. It is believed that this
eﬀect plays a substantial role in endosomal escape of
siRNA inside cells after endocytosis.
28-30 Nevertheless,
PLLincombinationwithprotonspongeligandssuchas
imidazole or histidine eﬀectively reduced the gene
expression; however, the toxicity of PLL dramatically
decreased when imidazole or histidines were attached
to PLL.
19,20 In the present investigation, we propose a
combination of PLL with a nontoxic PAMAM-NHAc
dendrimer that possesses several internal tertiary
amine groups. It is expected that these groups will
induce osmotic swelling of the endosome due to
endosomal buﬀering and lead to the rupture of en-
docytotic vesicles and subsequent release of their
payload. Furthermore, polyethylene glycol (PEG) was
included in the nanocarrier to enhance siRNA stability
against nuclease enzymes during the voyage in the
human bloodstream. We also achieved a decrease in
cytotoxicity of PLL by attaching a nontoxic PAMAM-
NHAc dendrimer and polyethylene glycol.
The ability of PLL, PEG-PLL, and PAMAM-PEG-PLL to
form a complex with siRNA was compared using the
agarose gel electrophoresis method. All three nano-
carriers formed astable complex ata N/Pratioof 1and
above. The numbers of cationic primary amine groups
were calculated based on PLL molecular weight and
degreeofpolymerization(∼8000Daand57,respectively).
Each PAMAM-PEG-PLL carrier (calculated Mw = 27650
Da) contained approximately 56 primary amine groups.
Similarly, cationic groups for PEG-PLL (calculated Mw =
11000 Da, DP 57) and PLL (Mw = 8000 Da, DP 57) were
calculated as 56 and 57, respectively. As expected, the
agarosegelelectrophoresisdatashowedthatPAMAM-
PEG-PLL was similar to the PEG-PLL and PLL ability to
form complexes with siRNA. Dynamic light scattering
data revealed an average size around 150 nm of the
resultingcomplexesoftheproposed nanocarrierswith
siRNA. This size of the resulting nanoparticles and possi-
ble impact of PLL as a penetration enhancer resulted
in the eﬃcient cellular uptake of triblock nanocarrier
PAMAM-PEG-PLL-siRNAcomplexesbyhumancancercells.
However, eﬀective uptake of siRNAby cells does not
automatically ensure eﬀective silencing of its targeted
mRNA.Forinstance,previously,wehaveshownthatan
eﬀective intracellular delivery of siRNA by dendrimers
doesnotguaranteeitshighgenesilencingactivity.
13,14
Down-regulation of a speciﬁcg e n eb ys i R N Ac a nb ec o n -
trolled by two possible contributing factors: (1) eﬀec-
tive cellular internalization of siRNA and (2) endosomal
Figure 4. Serum stability of naked and complexated siRNA.
(a) Representative images of agarose gel electrophoresis of
naked siRNA and PAMAM-PEG-PLL-siRNA complexes. (b)
Quantitative analysis of band intensity. Means ( SD are
shown.
Figure5. Expression of BCL2gene inA2780humanovarian
cancer cells incubated with (1) control (fresh media); (2)
nakedBCL2siRNA;(3)nakednonspeciﬁcsiRNA;(4)PAMAM-
BCL2 siRNA; (5) PAMAM-PEG-BCL2 siRNA; (6) PLL-BCL2
siRNA; (7) PEG-PLL-BCL2 siRNA; (8) PAMAP-PEG-PLL-BCL2
siRNA; (9) PAMAP-PEG-PLL-BCL2 nonspeciﬁc siRNA. Means
(SDareshown.*P<0.05whencomparedwithcontrol.
†P<
0.05 when compared with PLL-siRNA.
‡P < 0.05 when
compared with PAMAM-siRNA.
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escape of the payload to perform the task. Some
cationic polymers used for siRNA delivery including
PLL polymer show an excellent penetration into the
cells, while demonstrating a relatively weak gene
knock down due to poor endosomal release of the
siRNA payload.
31 The PAMAM dendrimer unit in the
triblock of the proposed nanocarrier PAMAM-PEG-PLL
provides the required tertiary amines for proton
sponge eﬀect and subsequent endosomal release of
the siRNA. We would like to note that proton sponge
eﬀect is only one possible mechanism of the release of
siRNA from the complex. The following mechanisms
can potentially be involved in the intracellular release
of siRNA. First, siRNA-carrier complex enters the cells
by endocytosis in membrane-limited endosomes that
eventually fuse with lysosomes. This leads to the sharp
decrease in pH disrupting electrostatic interactions
between the nucleic acid and carrier and ultimately
leading to the siRNA release. Second, lysosomal en-
zymes and the acidic environment can either degrade
or swell polymers, stimulating the release of siRNA
from the nanoparticle.
32 Third, polymers can them-
selves possess some membrane disruptive properties.
They can swell and burst the endosome through
protonation of excess amine groups.
33 The exact me-
chanisms of intracellular release of siRNA require
further more detailed investigation.
Thus, the PAMAM-PEG-PLL nanocarrier fulﬁlls both
the requirements of an eﬀective delivery system of
improved penetration and delivery of siRNA to the
cytoplasm to achieve desired gene knock down. The
role of the PAMAM dendrimer was conﬁrmed by
comparing the gene silencing eﬃciency of the BCL2
gene of siRNA complexed with triblock PAMAM-PEG-
PLL,PLL,andPEG-PLLnanocarriers.Indeed,thetriblock
nanocarrier PAMAM-PEG-PLL-siRNA showed maxi-
mum suppression of the expression of the targeted
BCL2 gene, while PLL alone or in combination with
poly(ethylene glycol) (PLL-PEG) led to a substantially
lower decrease in the expression of this gene.
After conﬁrming the role of PLL and PAMAM in the
triblock nanocarrier PAMAM-PEG-PLL, we further ex-
plored the role of PEG to protect the siRNA during the
voyage in the human bloodstream. Nuclease enzyme
degradation of siRNA in the blood serum is one of the
major obstacles forthe invivo therapeutic applications
ofthesiRNA.WeandothershavereportedthatPEGyla-
tion of siRNA or nanocarriers greatly improved the
stability of the siRNA in the human blood serum.
34-38
Thoughtheexactmechanismsofsuchstabilizationare
not clear, one can assume that siRNA is shielded by a
linearpolymerpolyethyleneglycolandthusminimizes
its exposure tothe nuclease enzymes. This assumption
isbasedonthefollowingconsiderations.AlthoughPEG
is a middle block of the nanocarrier, it is also a hydro-
philicsegmentandthereforeonecanexpectamicelle-
like geometry of the complex. Though we do not have
any evidence, we believe that the triblock nanocarrier
on complexation with siRNA forms a micelle wherein
the hydrophilic region (PEG) encapsulates the PLL/
siRNA complex. As expected, siRNA complexed with
the proposed triblock nanocarrier PAMAM-PEG-PLL
showed excellent siRNA stability in human blood
serum. In fact, complexated siRNA was stable in the
human serum more than 48 h, while naked siRNA
degraded in less than 6 h.
CONCLUSIONS
A triblock nanocarrier was designed, synthesized,
and evaluated for the eﬃcient delivery of siRNA. The
multifunctional triblock nanocarrier is synthetically
simple to prepare and provides a solution to several
obstacles involved in therapeutic applications of
siRNA.
METHODS
Materials. Generation four PAMAM-NH2 dendrimers (Mw ∼
14214Da,64amineendgroups),PLL3HBr(Mw∼12000,degree
of polymerization equal to 57), 4-(methylamino)pyridine, and
methyliodidewerepurchasedfromSigma-AldrichCo.(St.Louis,
MO). R,ω-Bis(2-carboxyethyl)polyethylene glycol (Mw ∼ 3000 Da)
and N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydro-
chloride were obtained from Fluka (Allentown, PA). Spectra/
Por dialysis membranes were obtained from Spectrum Labora-
tories, Inc. (Rancho Dominguez, CA). Ethidium bromide (EtBr)
solution was purchased from Promega (Madison, WI). The
sequence of siRNA targeted to BCL2 mRNA custom synthesized
by Ambion (Austin, TX) was 50-GUG AAG UCA ACA UGC CUG
C-dTdT-30 (sense strand) and 50-GCA GGC AUG UUG ACU UCA
C-dTdT-30 (antisense strand). Nonspecific siRNA used as a
negative control (sense strand, 50-CCU CGG GCU GUG CUC
UUU U-dTdT-30; antisense strand, 50-AAA AGA GCA CAG CCC
GAG G-dTdT-30) was received from Dharmacon Inc. (Lafayette,
CO).FluorescentRNAduplex,siRNAlabeledwithPierceNuLight
DY-547 fluorophores (siGLO Red Transfection Indicator, red
fluorescence), was obtained from Applied Biosystems
(Ambion, Inc., Foster City, CA). All other chemicals were pur-
chased from Fisher Scientific (Fairlawn, NJ).
Cell Line. The human ovarian carcinoma A2780 cell line was
obtained from Dr. T. C. Hamilton (Fox Chase Cancer Center).
Cells werecultured in RPMI1640medium (Sigma, St.Louis, MO)
supplemented with 10% fetal bovine serum (Fisher Scientific,
Fairlawn, NJ). Cells were grown at 37 C in a humidified atmo-
sphere of 5% CO2 (v/v) in air. All experiments were performed
on cells in the exponential growth phase.
SynthesisofSurface-ModifiedPAMAMDendrimer(PAMAM-NHAc). The
surface-modified and partially acetylated PAMAM-NHAc den-
drimer was prepared using a previously reported procedure
13
(Scheme 1). Briefly, triethylamine (0.11 mL, 0.82 mmol) was
added to a stirred solution of PAMAM-NH2 generation four
dendrimer (172 mg, 0.012 mmol) dissolved in anhydrous
methanol (10 mL) followed by the addition of excess acetic
anhydride (0.08 mL, 0.72 mmol). The resulting mixture was
stirred at room temperature for 24 h. Methanol was evaporated
underreducedpressureandtheresultingresiduewasdissolved
inwater(2mL).Furtherpurificationbyextensivedialysisagainst
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deionized water using dialysis membrane (molecular mass
cutoff = 2000 Da) and freeze-drying afforded acetylated PA-
MAM dendrimer. The degree of acetylation was confirmed by
proton nuclear magnetic resonance (
1H NMR).
Synthesis of PAMAM-PEG-COOH Conjugate. R,ω-Bis(2-carboxyethyl)-
polyethyleneglycol(15mg,5μmol,Mw∼3000Da)andPAMAM-[-
(NHAc)58(NH2)6] dendrimer (83 mg, 5 μmol) were dissolved in the
mixture of anhydrous solvents of methylene chloride (5 mL) and
dimethyl sulfoxide (5 mL) (Scheme 1). After stirring for 10 min at
room temperature, N-(3-dimethylaminopropyl)-N-ethylcarbodii-
mide hydrochloride (EDC3HCl) (1 mg, 5.3 μmol) and 4-(methyl-
amino)pyridine (DMAP) (0.5 mg) were added to the reaction
mixture. The resulting mixture was stirred for an additional 36 h
at room temperature, and solvents were removed under reduced
pressure. The residue was dissolved in water and purified by
extensive dialysis using Spectra/Por dialysis membrane (molecular
weight cutoff, MWC = 6000 Da) against deionized water. The
conjugate was further purified by passing through a Sephadex
G10 column using water as eluent and lyophilized to obtain
PAMAM-PEG-COOH as a white solid.
Synthesis of PAMAM-PEG-PLL Conjugate. Triethylamine (0.2 mL)
was added to a stirred solution of poly-L-lysine hydrobromide
(22 mg, 1.83 μmole, Mw = ∼12000, degree of polymerization
equal to57)inanhydrousdimethyl sulfoxide(3 mL)(Scheme 1).
The reaction mixture was further diluted with anhydrous
methylene chloride (5 mL) followed by the addition of PA-
MAM-PEG-COOH conjugate (22 mg, 1.14 μmol) and stirred at
room temperature for 15 min. EDC3HCl (1.5 mg, 7.8 μmol) and
DMAP (0.5 mg) were added to the reaction mixture. The
resulting solution was stirred for an additional 36 h at room
temperature. The side product carbodiimide urea was filtered
off, and solvents were removed under reduced pressure. The
residuewasdissolvedinwaterandpurifiedbyextensivedialysis
using Spectra/Por dialysis membrane (MWC = 25000 Da)
against deionized water. The conjugate was further purified
by passing through a Sephadex G10 column using water as
eluent and lyophilized to obtain PAMAM-PEG-PLL as a hygro-
scopic white solid.
Synthesis of PEG-PLL Conjugate. NHS-PEG-OMe(15.6mg,3.1μmol,
Mw = ∼5000) in phosphate buffer (pH 8.4) was added to a stirred
solution of poly-L-lysine hydrobromide (22 mg, 1.83 μmole, Mw =
∼12000, degree of polymerization equal to 57) in phosphate
buffer (pH 8.4). The resulting solution was stirred for 6 h at room
temperature. The resulting reaction mixture was then dialyzed
against 1 N HCl for 12 h and subsequently extensively dialyzed
against deionized water using dialysis membrane Spectra/Por
(MWC = 8000 Da). Further purification by passing through a
Sephadex G10 column using water as eluent and freeze-drying
afforded the PEG-PLL conjugate.
Synthesis of PAMAM-PEG-PLL-Cy5.5. Cy5.5 mono-NHS ester (1.5 mg,
1.32 μmol) dissolved in anhydrous dimethyl sulfoxide (1 mL) was
added to a stirred solution of PAMAM-PEG-PLL (9 mg, 0.32 μmol,
Mw∼28000) in0.1mMNaHCO3(1mL).Theresultingmixturewas
stirred in the dark at room temperature for 6 h. Extensive dialysis
using Spectra/Por dialysis membrane (MWC = 25000) against
deionized water was carried out to remove unreacted Cy5.5.
Additionally, the conjugate was purified by passing through a
Sephadexcolumn.TheconcentrationofCy5.5dyeattachedtothe
PAMAM-PEG-PLL nanocarrier was estimated by measuring its
fluorescence (excitation 675 nm, emission 694 nm) using Cy5.5
NHS ester as standard.
Proton Nuclear Magnetic Resonance Spectroscopy (
1H NMR).
1H NMR
was performed ona Varian VNMRS 400 MHz NMRspectrometer
(Varian, Inc., Palo Alto, CA). The chemical shift was expressed as
parts per million (ppm), and a solvent peak was used for
reference (D2O, 4.8 ppm). The following abbreviations are used
in the Results section to identify multiplicities of spectra peaks:
s, singlet; m, multiplet; br, broad.
In Vitro Cytotoxicity. A modified MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) assay was used to as-
sess the cyctotoxicity of the following nanocarriers PEG, PLL,
PEG-PLL, PAMAM-NH2, PAMAM-OH, PAMAM-NHAc, and PAMAM-
PEG-PLL as previously described.
39,40 To measure cytotoxicity,
cells were separately incubated in a microtiter plate with different
concentrations of PLL, PEG-PLL, and PAMAM-PEG-PLL. Control
cells received an equivalent volume of fresh medium. The
duration of incubation was 24h.On thebasis ofthese measure-
ments, cellular viability was calculated for each nanocarrier
concentration. A decrease in the cellular viability indicated an
increase in the toxicity.
CharacterizationofsiRNAComplexationwithNanocarriers. Thecom-
plexes ofcationic nanocarriers (PLL,PEG-PLL, andPAMAM-PEG-
PLL) and siRNA were prepared in water at N/P (amine/
phosphate) charge ratios ranging from 0 to 1.5 and incubated
atroomtemperaturefor30min.Thechargeratiowascalculated
byrelatingthenumberofcationicprimaryaminegroupsonthe
nanocarrier with the number of negatively charged phosphate
groups of siRNA. Dendrimer-free siRNA was used as the control.
Double-stranded RNA ladder (New England Biolabs, Ipswich,
MA) with the smallest base pairs at 21 was used as a size
reference. The samples were further diluted with DPBS buffer
and electrophoresed in 4% agarose gel at 100 V for 50 min in
Tris-borate-EDTA buffer containing ethidium bromide. The
siRNA bands on the gel were visualized under ultraviolet light
and photographed. Complex formation was also quantified by
measuring fluorescence of ethidium bromide in the sample
at 530 nm excitation and 590 nm emission wavelengths.
41
The fluorescence intensity at N/P charge ratio equal to 0 was
set to 100%.
DynamicLightScattering(DLS)AnalysisandZeta-Potential. PAMAM-
PEG-PLL-siRNA complex was prepared by mixing PAMAM-PEG-
PLL and siRNA in water at a N/P ratio equal to 3. The resulting
complexwasincubatedfor30min,andthesizewasdetermined
using the DynePro-MS800 dynamic light scattering/molecular
sizing instrument with an argon laser wavelength λ = 830 nm, a
detector angle 90, and typical sample volume of 20 μL. Each
light scattering experiment consisted of 20 or more indepen-
dent readings, 10 s in duration each. Data analysis was conducted
using DynaPro Instrument Control Software for molecular
Research DYNAMICS (version 5.26.60). The obtained DLS data
represent the average of three runs. Zeta-potential was mea-
suredonPALSZetaPotentialAnalyzer(BrookhavenInstruments
Corp,NewYork,NY).Samplesweretakenasis,andtheirvolume
was 1.5 mL. All measurements were carried out at room
temperature. Each parameter was measured five times, and
average values were calculated.
Cellular Internalization. Cellular uptake and intracellular loca-
lization of siRNA was investigated using a confocal microscopy.
In this experiment, living cancer cells were incubated with
fluorophore-labeled naked siRNA (siGLO Red, red fluorescence)
and siRNA complexed with cationic nanocarrier PAMAM-PEG-
PLL (N/P = 3). Cellular uptake substances were monitored in
living cells placed in a chamber at 37 C within 1 h. Cellular
localization of siRNA was examined on fixed and washed cells
after the incubation for 24 h with the substances. Fluorescence
and its distribution within the cell were examined using a
confocal microscope.
Gene Expression. Reverse transcription polymerase chain re-
action (RT-PCR) was used for the analysis of gene expression as
described previously.
40 The cationic nanonarrier (PLL, PLL-PEG-
OMe, and PAMAM-PEG-PLL)-siRNA (for BCL2 gene) complexes
were added to the cells with the final concentration of siRNA
equalto1μM.After24h,totalcellularRNAwasisolatedusingan
RNeasykit(Qiagen,Valencia,CA).First-strandcDNAwassynthe-
sized by Ready-To-Go You-Prime First-Strand Beads (GE Health-
care, Piscataway, NJ) with 2 μg of total cellular RNA and 100 ng
of random hexadeoxynucleotide primer (Amersham Bios-
ciences, Piscataway, NJ). After synthesis, the reaction mixture
was immediately subjected to polymerase chain reaction (PCR),
which was carried out using GenAmp PCR System 2400(Perkin-
Elmer, Shelton, CT). β2-microglobulin (β2-m) was used as an
internal standard. The following pairs of primers were used:
BCL2:5 0-GGA TTG TGG CCT TCT TTG AG-30 (sense), 50-CCA AAC
TGA GCA GAG TCT TC-30 (antisense); β2-m (internal standard)-
ACC CCC ACT GAA AAA GAT GA (sense), ATC TTC AAA CCT CCA
TGATG(antisense).PCRregimenwasasfollows:94Cfor5min;
94Cfor1min,55Cfor1min,and72Cfor1minfor41cycles;
and 60 C for 10 min. PCR products were separated in 4%
NuSieve 3:1 Reliant agarose gels (Lonza, Basel, Switzerland) in
1 Tris-borateEDTAbuffer[0.089mol/LTris-borate,0.002mol/L
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EDTA (pH 8.3); Research Organics Inc., Cleveland, OH] by sub-
marine electrophoresis. The gels were stained with EtBr and
digitally photographed.
Serum Stability of siRNA and PAMAM-PEG-PLL-siRNAComplex. Serum
stabilities of naked siRNA and siRNA complexed with PAMAM-
PEG-PLL nanocarrier were investigated by incubating siRNA or
PAMAM-PEG-PLL-siRNAcomplexin50%humanserumat37C.
Ten samples were prepared by mixing siRNA (30 nmol) in water
withPAMAM-PEG-PLL(74.8nmol,N/P=3)solutioninwaterand
separately incubated for 30 min at room temperature. In the
case of naked siRNA, equal volume of RNAase-free water was
used instead of nanocarrier. To each of these samples was added
50% human plasma (final siRNA concentration was 1.43 nM)
and incubated at 37 C. Samples were removed at indicated
time intervals (0, 0.25, 0.5, 0.75, 1, 3, 6, 12, 24, and 50 h) and
analyzedusingagelelectrophoresis(4%agarosegelat100Vfor
50 min) in Tris-borate-EDTA buffer containing EtBr. The siRNA
bands on the gel were visualized under ultraviolet light. PAMAM-
PEG-PLL-siRNA samples were pretreated with polymethacrylic
acidtoreleasefree siRNAfromcationicnanocarriers.Then,100μL
of polymethacrylic acid solution (4 μM) was added to the com-
plexes(triblocknanocarrier/siRNA=3)andincubatedat37Cwith
50% human plasma. The released siRNA was then analyzed by
gel electrophoresis.
Statistical Analysis. Data obtained were analyzed using de-
scriptive statistics, single factor analysis of variance (ANOVA)
and presented as a mean value ( standard deviation (SD) from
five independent measurements. We analyzed data sets for
significancewithStudent'sttestandconsideredPvaluesofless
than 0.05 as statistically significant.
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